Sebastian Wehle
Director/Board Member chez TIGENIX NV
Profil
Sebastian Wehle is currently working as an Executive Director at TiGenix NV since 2018.
Prior to this, he worked as the Head-Alofisel Manufacturing & Supply at Takeda Pharmaceutical Co., Ltd.
Dr. Wehle holds a doctorate degree from the University of Kiel.
Postes actifs de Sebastian Wehle
| Sociétés | Poste | Début |
|---|---|---|
| TIGENIX NV | Director/Board Member | 15/06/2018 |
Anciens postes connus de Sebastian Wehle
| Sociétés | Poste | Fin |
|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
Formation de Sebastian Wehle
| University of Kiel | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
